March 29 (Reuters) - Britain's FTSE 100 index is seen opening 20 points lower at 7,025 on Thursday, according to financial bookmakers.
* CME/NEX: U.S. exchange operator CME Group (NASDAQ: CME ) is in advanced talks to buy Britain's NEX Group for about 3.8 billion pounds ($5.4 billion) to create a cross-border trading powerhouse.
* SHIRE: Japan's largest drugmaker Takeda Pharmaceutical is considering a bid for London-listed rare disease specialist Shire that could top $40 billion and spark another takeover battle in the deal-hungry pharma industry.
* RECKITT BENCKISER: Reckitt Benckiser's chief executive Rakesh Kapoor got an 18 percent pay cut in 2017, his second in two years, due to a halving of his long-term incentive benefits, after a year of underperformance at the British consumer goods company.
* GKN/MELROSE: The three-month battle for GKN (LON: GKN ) will be decided on Thursday when the deadline for shareholders to accept Melrose Industries's 8 billion pound ($11 billion) hostile bid expires, ending one of the most closely-contested takeover fights in Britain for years.
* GSK/TEVA: A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries (NYSE: TEVA ) Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.
* UK CAR OUTPUT: British car production fell 4.4 percent in February, dragged down by the seventh consecutive monthly decline in domestic demand as sales in Europe's second biggest car market continue to slump, an industry body said on Thursday.
* EX-DIVS: British Land, Intercontinental Hotel Group and Prudential (LON: PRU ) will trade without entitlement to their latest dividend pay-out on Thursday, trimming 3.88 points off the FTSE 100 according to Reuters calculations.
* The UK blue chip index closed up 0.6 percent at 7,044.74 points on Wednesday, shaking off broader concerns over the U.S. tech sector that rattled global equity markets. Shares in pharma firm Shire surged.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.